iBio (IBIO, Financial) has entered into a licensing agreement with AstralBio for a groundbreaking preclinical antibody that targets Activin E. This antibody was developed using iBio's proprietary Machine-Learning Antibody Engine.
Activin E represents a novel target in therapeutic research with the potential to induce fat-selective weight loss. Inhibiting Activin E may provide protection against obesity and related cardiometabolic conditions.
Following promising preclinical outcomes, where the antibody demonstrated effective binding and inhibition of Activin E signaling, along with inducing fat-specific weight reduction in obese rodent models, iBio aims to expedite testing in more complex models.
